

EDITORIAL VIEWS

Robotic anesthesia – how far from reality?

Yazan Chaiah, Amer Majeed

251-254

[PDF](#) [HTML](#)

Lung recruitment maneuver: is it really safe?

Hanik Badriyah Hidayati, Bambang Pujo Semedi, Prananda Surya Airlangga, Nancy Margarita Rehatta, Mahmud .

255-261

[PDF](#) [HTML](#)

A life without pain

Carlos R Degrandi Oliveira

262-264

[PDF](#) [HTML](#)

PERSPECTIVES

Anesthetic management of rare diseases - OrphanAnesthesia Project

Carlos R Degrandi Oliveira

265-266

[PDF](#) [HTML](#)

ORIGINAL RESEARCH

Coping Strategies Scale for myocardial infarction survivors

Muhammad Rafiq, Tanzeela Khaliq

267-273



PDF



HTML

A double blind randomized clinical trial to compare the efficacy of bupivacaine and ropivacaine for painless delivery

Alireza Kamali, Narges Anousheh, Maryam Shokrpour, Shirin Pazouki

274-279



PDF



HTML

Evaluation of tissue oxygenation in cesarean cases under spinal anesthesia: A prospective observational study

Abdullah Özdemir, Ayşe Hizal, Başar Erdivanli, Seyfi Kartal, Ahmet Şen

280-286



PDF



HTML

The effect of celecoxib on early postoperative cognitive dysfunction in elderly patients of fracture neck of femur: a prospective randomised double-blind study

Manish Kumar Singh, Santosh Kumar, Priya Dixit, Vinita Singh, Sateesh Verma, Gyan Prakash Singh

287-294



PDF



HTML

Efficacy of tocilizumab in critically ill COVID-19 patients: a retrospective cohort

Sairah Sadaf, Babar Bashir, Syeda Sabahat Haider, Ghulam Mustafa, Syed Aushtar Abbas Naqvi

295-302

 PDF

 HTML

Determination of predictive factors for intensive care unit admission following robot-assisted radical cystectomy

Firdevs Tugba Bozkurt, Erem Asil, SevalIzdes .

303-309

 PDF

 HTML

Bacterial bloodstream infections in medical and surgical intensive care units: a study of distribution and susceptibility patterns

Bharath Cherukuri, Vijay Anand Siva Kumar, Nageswara Rao Murupudi

310-317

 PDF

 HTML

COVID-19 at the emergency department

Ensar Durmus, Fatih Guneyusu

318-323

 PDF

 HTML

Comparison of postoperative pain in photorefractive keratectomy using topical versus oral nonsteroidal anti-inflammatory drugs

Sanwal Javaid, Marrium Shafi, Yaseen Lodhi

324-328

 PDF

 HTML

Correlation of pulse pressure variation with central venous pressure for intra-operative fluid management in adult neurosurgical patients

Pratika Pradeep Bhokare, Shalaka Nellore, Hemangi Karnik

329-337

 PDF

 HTML

Evaluation of gum elastic bougie guided Proseal laryngeal mask airway insertion technique

Deepak Narang, Manoj Kumar Upadhyay, Geetesh Kumar, Ajay Chaurasia

338-344

 PDF

 HTML

Effect of propofol on circadian variation of brain-derived neurotrophic factor

Muhammad Rafiq

345-348

 HTML

Extraordinary days, unusual circumstances: psychosocial effects of working with COVID-19 patients on healthcare professionals

Kubra Fadiloglu, Esra Gurbuz, Nazim Yildiz, Omer Aydin, Ezgi Tanriover Aydin

349-358

 PDF

 HTML

Pre-emptive intravenous paracetamol vs. ketorolac for shoulder pain in cesarean section under spinal anesthesia: A randomized double-blind placebo-controlled trial

Intravenous paracetamol and ketorolac effect on tip shoulder pain in cesarean section under spinal anesthesia

Mohammad Yasin Karami, Laleh Dehghanpisheh, Simin Azemati, Farnaz Feiz

359-368

 PDF

 HTML

REVIEW ARTICLE

Pearls of Exercise-based Cardiac Rehabilitation Frame in Post Coronary Artery Bypass Graft

Ivana Purnama Dewi, Kristin Purnama Dewi, Tiniwati Tanojo, Eka Prasetya Budi Mulia, Meity Adriana

367-376

 PDF

 HTML

Restarting elective surgery during the COVID-19 pandemic

Mahendratama Purnama Adhi, Agus Suhendar, Bagus Fajar Rohman, Edi Hartoyo

376-382

[PDF](#) [HTML](#)

Intra- and inter-hospital transportation of a COVID-19 patient; observing safety of the patient, the health worker and the community

Yusuf Bara Jibrin, Ballah Abubakar, Zuwaira Hassan, Ibrahim S. Abdullahi, Maigari Ibrahim, Lawan Suleiman

383-386

[PDF](#) [HTML](#)

Antiviral therapy for COVID-2019

Hanik Badriyah Hidayati, Evi Octavia, Cempaka Thursina Srisetyaningrum

387-390

[PDF](#) [HTML](#)

CASE REPORTS

Anesthetic management for tracheal stent removal with severe scar stenosis

Ting Yang, Muhammad Saqib Mudabbar, Qiang Fu, Bin Liu

391-394

[PDF](#) [HTML](#)

Perioperative anesthesia management of a pregnant patient with COVID-19 and Guillain-Barre syndrome undergoing emergency cesarean section – a case report

Anwar ul Huda ., Ashraf M. Deabes

395-398

[PDF](#) [HTML](#)

Anesthetic management for endoscopic retrograde cholangiopancreatography in bronchobiliary fistula: a case report

Salman Shahzad, Tahira Younus, Eitzaz Ud Din Khan

399-401

[PDF](#) [HTML](#)

A rare case of low backache (Bertolotti's syndrome)

Liaquat Ali, Khaleel Ahmed, Umer Ali

402-405

[PDF](#) [HTML](#)

LETTERS TO EDITOR

An aberrant lateral femoral cutaneous nerve: superficial to sartorius is the norm but not the rule

Manish Keshwani, Habib Md Reazaul Karim, Samarjit dey, Jitendra V Kalbande

406-407

[PDF](#) [HTML](#)


Necessity of a change in AHA CPR guidelines 2020 for pregnant women

Text

Behnam Farahmandnia, Asad Imani

408-409

 PDF

 HTML

CORRESPONDENCE

Interpretation and reproducibility of echocardiography studies in critically ill patients.

Filippo Sanfilippo, Stephen Huang, Prof. Antoine Vieillard-Baron, Prof

410-411

 HTML

CLINIQUIZ

Current Scenario in COVID- 19

Sweety Dutta, Priyanka ., Pranav Bansal

412-415

 PDF

 HTML

BOOK REVIEW

Clinical Pearls in Interventional Pain Management

Tariq Hayat Khan

416-417

 PDF

 HTML

OBITUARY

Dr. Taj Muhammad Chaudhary

Dr. Syed Zia Haider, Prof.

418

[PDF](#) [HTML](#)

Dr Sri Ram Mallavarapu

Dr. Siddha SC Chakra Rao

419

[PDF](#) [HTML](#)

Editorial Team

PATRON



Brig (Retd) M. Salim, SI (M), DA, FFARCS, FCPS, PhD

Professor of Anesthesiology & Pain Medicine

Founder member, Pakistan Society of Anesthesiologists (PSA)

Founder, Past President & Patron, Society for Treatment & Study of Pain (STSP®)

E-mail: brigsaleem1@gmail.com

EDITOR-IN-CHIEF



Tariq Hayat Khan, MBBS, DA, MCPS, FCPS

Consultant Anesthesiologist & Pain Specialist,

President, Pakistan Resuscitation Society (PARES)

Cell: +92-321-5149709

E-mail: apicarejournal@gmail.com

Senior Editor:



Fauzia Anis Khan, LRCP, MRCS, FRCA, MCPS, FCPS, (Pakistan)

Department of Anaesthesia, The Aga Khan University, Karachi

Ex-HoD/Interim Associate Dean, Postgraduate Medical Education, Aga Khan University, Karachi (Pakistan)

E-mail: fauzia.khan@aku.edu

Associate Editors



AKM Akhtar uz Zaman (Bangladesh)
Professor of Neuroanaesthesia,
Fellowship in Anaesthesia and Pain Medicine in Tokya (Japan).
E-mail: akm.akhtaruzzaman@bsmmu.edu.bd



Pranav Bansal, MBBS, MD (Anesthesiology) (India)
Professor & Head, Dept. of Anesthesiology
BPS Govt. Medical College, Khanpur Kalan, Sonipat, Haryana, (India)
E-mail: pranavbansal1@gmail.com



Logan Danielson, MD, MBA (USA)
Children's Hospital of Michigan, Detroit, MI
Research Assistant for Michigan Pediatric Surgical Associates, Detroit, MI (USA)
E-mail: logandanielson@gmail.com

ASSISTANT EDITORS



Muhammad Faisal Jafar, MBBS, MCPS, FCPS (Pak), FRCA (UK)
Consultant Anaesthetist, St John's Hospital, Livingston, Scotland
Address: 58c Gracemount Drive, Edinburgh, EH17 8DA (UK).
E-mail: faisaljafar@yahoo.com



Somaye Pouy

PhD Student of Nursing Education

Instructor at Guilan University of Medical Sciences, Rasht, Iran

Email: Somayepouy@gmail.com



Mishal Fatima, MBBS, FCPS (I) (Pakistan)

Department of Surgery,

Islamabad Medical Complex, Islamabad (Pakistan)

E-mail: mishalfati@gmail.com

STATISTICIAN

Shamail Alam

Punjab Institute of Cardiology, Lahore (Pakistan)

E-mail: shamailalam@gmail.com

EDITORIAL BOARD Members



Aliya Ahmed, FFARCSI (Pakistan)

Professor of Anaesthesiology

Director, Residency Programme in Anaesthesia, Agha Khan University Hospital Karachi (Pakistan).

E-mail: aliya.ahmed@aku.edu



Arshad Taqi, FCPS, (Pakistan)

Professor of Anesthesiology,

Hameed Latif Hospital & Medical College, Garden Town, Lahore

Consultant Anesthesiologist, Kaul Anesthesia Associates (Pvt) Ltd., Lahore (Pakistan)

E-mail: arshadtaqi@gmail.com

MINI REVIEW

CORONA EXPERIENCE

Antiviral therapy for COVID-2019

Hanik Badriyah Hidayati ¹, Evi Octavia ², Cempaka Thursina Srisetyaningrum ³

Author affiliations:

1. Neurology Department, Faculty of Medicine, Universitas Airlangga/ Dr. Soetomo General Hospital, Surabaya - Indonesia.
2. Hospital Pharmacy Installation of Dr. Soetomo General Hospital, Surabaya, East Java, Indonesia.
3. Neurology Department, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta - Indonesia.

*Correspondence: Hanik Badriyah Hidayati; E-mail: hanikhidayati@fk.unair.ac.id.

Abstract

The whole world is experiencing a global pandemic caused by Coronavirus disease 2019. As the pandemic progresses, there has been much research on antiviral drugs, such as hydroxychloroquin, chloroquine, remdesivir, lopinavir-ritonavir, favipiravir, oseltamivir, and umifenovir. Specific antiviral drugs proven to be effective against SARS-CoV-2 have not been found and approved for the medication of COVID-19. Currently, case detection, infection control, monitoring, prevention, and supportive care are the means focused on the treatment of COVID-19. A large scale research is currently underway to analyze safety and efficacy of antiviral drugs, while trials of the SAR-CoV-2 vaccine are rapidly expanding. This mini review briefly introduces the current antiviral therapy for COVID-19.

Key word: Antiviral therapy; Drugs; COVID-19

Citation: Hidayati HB, Octavia E, Srisetyaningrum CT. Antiviral therapy for COVID-2019. *Anaesth. pain intensive care* 2021;25(3):387–390. DOI: [10.35975/apic.v25i3.1522](https://doi.org/10.35975/apic.v25i3.1522)

Received: January 8, 2021; **Reviewed:** March 11, 2021; **Accepted:** March 11, 2021

1. Introduction

The whole world is experiencing a global pandemic caused by Coronavirus disease - 2019.¹ Based on data according to the World Health Organization, Globally, as of 18 May 2021, there have been 163,312,429 confirmed cases of COVID-19, including 3,386,825 deaths, reported to WHO. As of 18 May 2021, a total of 1,407,945,776 vaccine doses have been administered.^{1,2} COVID-19 infection rates continue to increase sharply.³ As of 18 May, 2021 there have been 880,362 confirmed cases and 19,617 deaths in Pakistan.¹

Compared to COVID-19, Severe Acute Respiratory Syndrome (SARS-CoV) had the incidence of 8,422 cases with a case fatality rate (CFR) of 11%, and the Middle East Respiratory Syndrome (MERS) 2574 laboratory-confirmed cases, including 886 associated deaths (case-fatality ratio 34.4%). While the

diagnostic criteria of COVID-19 is still being periodically reviewed, it might take years for the actual number of cases to be known.⁴ As the pandemic progresses, there has been extensive research on antiviral drugs, namely hydroxychloroquin, chloroquine, remdesivir, lopinavir-ritonavir, favipiravir, oseltamivir, and umifenovir.⁵ We present here an overview of the current anti-viral drugs being used.

2. Antiviral therapy

Due to the clinical manifestations of COVID-19 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication, antiviral therapy that can treat COVID-19 is being investigated. Mechanism of action of antiviral drugs is by inhibiting the entry of the virus (by transmembrane serine

Antiviral Therapy

protease 2 (TMPRSS2) and the angiotensin-converting enzyme 2 (ACE2) receptor; fusion inhibitors inhibit the fusion process and endocytosis or the action of the RNA-dependent RNA polymerase and the SARS-CoV-2 3-chymotrypsin-like protease (3CLpro).^{3,6,7} Antivirals may have the biggest impact because viral replication is probably very active initially in the progression of COVID-19 before the disease moves to the high inflammation syndrome state that can lead towards the next step of disease inclusive of hypercritical stage. Therefore, the role of antiviral drugs needs to be understood in curing minor, moderate, major and critical disease, so that the treating physicians may optimize medication for the COVID-19 patients.^{3,6}

In clinical trials antiviral therapy was investigated to find the efficacy of SARS-CoV-2 treatment. It is reported that single therapy or combinations therapy for the COVID-19 patients differs in different countries of the world. These methods of therapy usually depend on the number of deaths and the frequency of mechanical ventilation the patients use. In addition, there is no specific medication for the COVID-19. Currently, various countries around the world have been investigating different antiviral therapies for the COVID-19 (Table 1).⁸ Specific antiviral drugs proven to be effective against SARS-CoV-2 have not been found and approved for the medication of COVID-19. Therefore, rapid assessment of the antiviral drugs currently available for use in COVID-19 patients is critical at this time of crisis, as well as for finding newer drugs.⁹

2.1. Antimalarial

2.1.1. Hydroxychloroquine and Chloroquine

Hydroxychloroquine and chloroquine are antimalarial drug. Hydroxychloroquine is a chloroquine analogue. June 15, 2020, the FDA withdrew the emergency use authorization for hydroxychloroquine, throwing out that it is unlikely to be effective in medicating COVID-19. In Addition, given the processing of that viral fusion does not occur, and cytokine release converting enzyme 2 (ACE2) cellular receptor, pyrazinecarboxamide derivative prodrug of a nucleoside analogue that can be triphosphorylated in and RNA polymerase of the virus, protein glycosylation, assembly of the virus, new virus

acidification of the cell membrane at the surface, so immunomodulation.¹⁰ Neither drugs are approved by FDA for the medication of COVID-19 patients. Have serious cardiac adverse events and other serious side effects (methemoglobinemia) of hydroxychloroquine do not justify its continued use.^{10,11} Chloroquine was introduced in 1934, while hydroxychloroquine was introduced in 1946.⁶ Hydroxychloroquine used to medicate systemic lupus erythematosus (SLE), rheumatoid arthritis, and also malaria. Normally, hydroxychloroquine has less and lower toxicity (including a small tendency to interval QTc prolongation) and minor drug-drug interactions than chloroquine (Table 1).⁶ Mechanisms may include inhibiting viral enzymes or processes such as DNA.

2.2. HIV Protease inhibitor

2.2.1. Lopinavir/Ritonavir

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication relies on the splitting of a helicase, and polyproteins become an RNA-dependent RNA polymerase. In the splitting, protease, which is responsible, namely: 3-chymotrypsin-like protease (3CLpro) and papain-like protease (PLpro).⁶ Ritonavir acts to increase plasma level of lopinavir by inhibiting the CYP3A-mediated metabolism of lopinavir.¹¹ The combined use of these drugs can increase the bioavailability of lopinavir significantly, and the effect of antiviral is improved in vivo.¹² Lopinavir and ritonavir have mechanism of action may bind to primary enzyme, it called Mpro, suppressing the replication of the coronavirus so that it does not occur. This can suppress activity of the corona virus.¹³ Lopinavir and ritonavir have been researched in patients with COVID-19. The clinical trials on lopinavir/ritonavir have not established their efficacy for the treatment of COVID-19.^{6,13} The common adverse events of lopinavir/ritonavir observed are diarrhea, nausea and vomiting, while severe adverse event include interval QTc prolongation and hepatotoxicity (Table 1).^{3,6}

2.3. Nucleotide reverse transcriptase inhibitor

2.3.1. Remdesivir and Favipiravir

Remdesivir is a nucleotide prodrug of an adenosine analog, and is infused intravenously. Favipiravir is a cells and acts as the virus RNA-dependent RNA polymerase (RdRp) substrate.¹²

Antiviral Therapy

Remdesivir and favipiravir inhibit viral replication through premature termination of RNA transcription.^{6,12} Food and Drug Administration (FDA) has approved remdesivir for the medication of COVID-19 in hospitalized pediatric patients of at least 40 kg and 12 years or older and the adults.¹¹ Remdesivir should be administered in a hospital or a healthcare setting that can provide the same level of care to an inpatient hospital.⁶ Remdesivir is administered as a loading dose 200 mg on day 1, followed by once daily 100 mg IV dose for a total of 10 days, similar to the doses used in the clinical trials to medicate Ebola for adults (Table 1).^{3,11} Remdesivir can lead to gastrointestinal symptoms such as nausea, raised levels of transaminase, an elevated time of prothrombin, and hypersensitivity reactions.⁶

Favipiravir was developed in Japan in 2014. Initial clinical trial outcome indicate that favipiravir produces much greater improvement in chest imaging in COVID-19 patients compared to lopinavir. Faster viral clearance and fewer adverse events were also viewed in patients taking favipiravir compared to those taking lopinavir-ritonavir.³ The most serious adverse events of favipiravir is teratogenicity. Common adverse events were gastrointestinal symptoms, liver enzyme abnormalities, raised serum uric acid, and psychiatric issues.¹²

Several clinical trials analyzing remdesivir and favipiravir for the medication of COVID-19 are currently underway or in development.⁶

2.4. Neuraminidase inhibitor (Virus release inhibitor)

2.4.1. Oseltamivir

Oseltamivir is inhibitor of a neuraminidase and is used to treat influenza A and B. It is also being researched for the medication of COVID-19. It has been reported potentially inhibiting the SARS-CoV-2. Case reports suggest a better prognosis in COVID-19 patients taking oseltamivir. However, oseltamivir efficacy for the medication of COVID-19 needs long term clinical trials.⁵

2.5. Fusion Inhibitor

2.5.1. Umifenovir

Umifenovir, also called as arbidol, is another antiviral agent which acts by inhibiting spike protein /ACE2 binding and fusion of viral envelopes providing antiviral effects. Initial studies showed that arbidol

medication was likely to raise the discharge rate and reduce the mortality rate for patients with COVID-19. Currently, arbidol effectiveness still has no clear evidence and needs further research.⁵

3. Conclusion

COVID-19 infection rates continue to increase sharply, as well as the number of antiviral drugs that work as a treatment for COVID-19. Currently, case detection, infection control, monitoring, prevention, and supportive care are the main focus in the treatment of COVID-19. No specific antiviral therapy has been confirmed to be effective in curing COVID-19. Studies are currently underway to analyze the safety and efficacy of antiviral drugs, while trials of the SAR-CoV-2 vaccines are rapidly expanding.

4. Conflict of Interest

The authors declare no conflict of interest.

5. Acknowledgement

The authors are thankful to Hanik Badriyah Hidayati for Checking plagiarism and Celine Anindytha for helping hyperlinking the references.

6. References

1. Wungu CDK, Khaerunnisa S, Putri EAC, Hidayati HB, Qumianingsih E, Lukitasari L, et al. Meta-analysis of cardiac markers for predictive factors on severity and mortality of COVID-19. *Int J Infect Dis.* 2021;105:551-9. [PubMed] DOI: [10.1016/j.ijid.2021.03.008](https://doi.org/10.1016/j.ijid.2021.03.008)
2. Organization W. Coronavirus disease (COVID-19) Situation Report. 2021. (Cited: March 20, 2021) Available from: <https://covid19.who.int/>
3. Lam S, Lombardi A, Ouanounou A. COVID-19: A review of the proposed pharmacological treatments. *Eur J Pharmacol.* 2020;886(May):173451. [PubMed] DOI: [10.1016/j.ejphar.2020.173451](https://doi.org/10.1016/j.ejphar.2020.173451)
4. Rochmawati N, Hidayati HB, Yamasari Y, Yustanti W, Rakhmawati L, Tjahyaningtjas HPA, et al. Covid Symptom Severity Using Decision Tree. *Proceeding - 2020 3rd Int Conf Vocat Educ Electr Eng Strength Framew Soc 50 through Innov Educ Electr Eng Informatics Eng ICVEE 2020.* 2020; (Cited: March 20, 2021) Available from: <https://ieeexplore.ieee.org/abstract/document/9243246>
5. Zhao M, Zhang J, Li H, Luo Z, Ye J, Xu Y, et al. Recent progress of antiviral therapy for coronavirus disease 2019. *Eur J Pharmacol.* 2021;890. [PubMed] DOI: [10.1016/j.ejphar.2020.173646](https://doi.org/10.1016/j.ejphar.2020.173646)
6. NIH. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Disponible en:

Antiviral Therapy

- <https://covid19treatmentguidelines.nih.gov/>. NIH. 2020;2019:130.
7. Nugraha D, Kloping NA, Yudhawati R, Purwandhono A, Hidayati HB. A current update in COVID-19 associated acute respiratory distress syndrome: Focus on mesenchymal stem cell therapy. *Anaesth Pain Intensive Care*. 2020;24(6):671–81. DOI: [10.35975/apic.v24i6.1404](https://doi.org/10.35975/apic.v24i6.1404)
 8. Kivrak A, Ulaş B, Kivrak H. A comparative analysis for antiviral drugs: Their efficiency against SARS-CoV-2. *Int Immunopharmacol*. 2021 Jan;90:107232. [PubMed] DOI: [10.1016/j.intimp.2020.107232](https://doi.org/10.1016/j.intimp.2020.107232)
 9. Frediansyah A, Tiwari R, Sharun K, Dhama K, Harapan H. Antivirals for COVID-19: A critical review. *Clin Epidemiol Glob Heal*. 2021 Jan-Mar;9:90-98. [PubMed] DOI: [10.1016/j.cegh.2020.07.006](https://doi.org/10.1016/j.cegh.2020.07.006)
 10. Smith T, Bushek J, Leclair A, Prosser T. COVID-19 Drug Therapy What' s been updated : Highlights : 2020; IBM Micromedex. DynaMed [cited 2012 Mar 15]. Available from: <https://www.dynamed.com/drugsbrowse>
 11. Wang D, Li Z, Liu Y. An overview of the saety, clinical application and antiviral research of the COVID-19 therapeutics. *J Infect Public Health*. 2020;13(10):1405–14. [PubMed] DOI: [10.1016/j.jiph.2020.07.004](https://doi.org/10.1016/j.jiph.2020.07.004)
 12. ASHP COVID-19 Resource Center. Assessment of Evidence for COVID-19-Related Treatments : Updated 4 / 10 / 2020 TABLE OF CONTENTS; 2020. p.1–138. Available from: <https://www.ashp.org/COVID-19?loginreturnUrl=SSOCheckOnly>
 13. Jolanda van Zuuren MD, Lacoviello Vito MD F. DynaMed. [cited 2021 Mar 15]. Available from: <https://www.dynamed.com/condition/covid-19-novel-coronavirus>

Antiviral Therapy

Table 1. Review of antiviral therapy to treat COVID-19^(3,8,11,13)

Drug	Mechanism of action	Trial or Clinical Experience	Dosage	Approved indication(s)	Adverse drug reaction	Drug interaction	country that use drugs
Remdesivir	inhibitor of RNA-dependent RNA polymerase	200 mg day 1 loading dose one times daily followed by 100 mg one times daily for a total of 10 days (IV)	200 mg day 1 loading dose one times daily followed by 100 mg one times daily for a total of 10 days (IV)	None	Common: Gastrointestinal:nausea (3-7%) Serious: cardiac arrest, Transaminase level raised, hepatotoxicity, anaphylaxis, hypersensitivity reaction (less than 2%), infusion reaction Gastrointestinal disturbances (nausea 10.3% vomiting 6.8% adult ,pediatric 12%, diarrhea adult 19.5%, pediatric 12%), raised transaminase,raised bleeding, insulin resistance , hyperlipidemia, hypoglycemia, , prolong of QT interval, possible renal dysfunction risk, steven-Johnson syndrom, central nervous depression, respiratory depression	<ul style="list-style-type: none"> • CYP3A4 inducers decrease effectiveness • Major Interaction: Chloroquine , Hydroxychloroquine • inhibitor of CYP3A4 and substrate of CYP2D6 • Contraindicated Interaction: Amiodaron, fluconazole, simvastatin, phenytoin, rifampin, ketoconazole 	Italy, Spain, Germany, South Korea, USA, China
Lopinavir-ritonavir (Kaletra)	inhibitor of 3CL protease	400mg/100 mg twice daily for maximum to 14 days (oral)	400mg/100 mg twice daily for maximum to 14 days (oral)	HIV	Gastrointestinal disturbances (nausea, vomiting, diarrhea), hyperuricemia, elevated transaminases, decreased neutrophil count	<ul style="list-style-type: none"> • Mainly mediated by aldehyde oxidase, not substrat CYPs 	Turkey
Favipiravir	inhibitor of RNA-dependent RNA polymerase	1600-1800 mg daily on day1, then 600 mg two times daily for 7-14 days (oral)	1600-1800 mg daily on day1, then 600 mg two times daily for 7-14 days (oral)	Ebola virus, Influenza A and B, Norovirus	Gastrointestinal disturbances (nausea, vomiting, diarrhea), hyperuricemia, elevated transaminases, decreased neutrophil count	<ul style="list-style-type: none"> • CYP3A4/5, 2D6, and 2C8 substrat • increased risk of prolonging QT interval with other QT prolongation agents (antibiotikquinolon, macrolide) raised digoxin levels • raised risk of hypoglycemia with blood glucose-lowering agents • major interaction: Azitromycin metabolized by CYP3A4: monitor closely CYP3A4 strong inducers/inhibitors • Antacids 	Italy, Spain, South Korea, USA, Brazil, China
Chloroquine Arelent)	inhibitor of Viral entry	500 mg orally one or two times daily for 5-10 days (oral)	500 mg orally one or two times daily for 5-10 days (oral)	Autoimmune disease: rheumatoid arthritis (RA), Systemic lupus erythematosus (SLE), malaria	Gastrointestinal disturbances (e.g, vomiting, diarrhea, nausea), headache, delirium, QT prolongation, Torsades de Pointes, arrhythmia, agranulocytosis, extrapyramidal disease, seizures, retina disorder rare renal toxicity, anorexia, bitter taste	<ul style="list-style-type: none"> • Major interaction: warfarin 	Italy, USA, China,
Hidroxychloroquine(Plaquenil)	inhibitor of Viral entry	Day 1 400 mg two times daily, followed by 200 mg two times daily for 5-10 days Alternative: 200 mg Three times daily for 10 days or 400 mg one daily for 5 days (oral)	Day 1 400 mg two times daily, followed by 200 mg two times daily for 5-10 days Alternative: 200 mg Three times daily for 10 days or 400 mg one daily for 5 days (oral)	Influenza A and B	Gastrointestinal disturbances (nausea), QT prolongation, hypoglycemia, neuropsychiatric effects, agranulocytosis, extrapyramidal disease, disorder muscle, hearing loss, angiodema	<ul style="list-style-type: none"> • Metabolized by CYP3A4: monitor closely CYP3A4 strong inducers/inhibitors 	Italy, Spain, Turkey, Russia, South Korea, Brazil
Osetamivir	Neuraminidas e inhibitor	75 mg every 12 hours (oral)	75 mg every 12 hours (oral)	Influenza A and B	Gastrointestinal disturbances (nausea 8-10%, vomiting 2-8% adult 8-16% pediatric), headache, cardiac dyrrhythmia, hepatitis, seizure, , anaphylaxis	<ul style="list-style-type: none"> • Metabolized by CYP3A4: monitor strong inducers/inhibitors of CYP3A4 	Russia
Umifenovir	Spike protein/ACE2 membrane fusion inhibitor	200 mg 3 times daily for duration of 7-10 days/longer (oral)	200 mg 3 times daily for duration of 7-10 days/longer (oral)	Influenza A and B	Gastrointestinal disturbances (nausea, vomiting), allergic reaction, elevated transaminases		

Antiviral Therapy